141 related articles for article (PubMed ID: 33299824)
1. Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases.
Tsang ES; Loree JM; Davies JM; Gill S; Liu D; Ho S; Renouf DJ; Lim HJ; Kennecke HF
Can J Gastroenterol Hepatol; 2020; 2020():5104082. PubMed ID: 33299824
[TBL] [Abstract][Full Text] [Related]
2. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review.
Jia Z; Wang W
Eur J Radiol; 2018 Mar; 100():23-29. PubMed ID: 29496075
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
Wong TY; Zhang KS; Gandhi RT; Collins ZS; O'Hara R; Wang EA; Vaheesan K; Matsuoka L; Sze DY; Kennedy AS; Brown DB
BMC Cancer; 2022 Mar; 22(1):224. PubMed ID: 35232410
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization.
Fan KY; Wild AT; Halappa VG; Kumar R; Ellsworth S; Ziegler M; Garg T; Rosati LM; Su Z; Hacker-Prietz A; Pawlik TM; Cosgrove DP; Hong KK; Kamel IR; Geschwind JF; Herman JM
Contemp Clin Trials; 2016 Sep; 50():143-9. PubMed ID: 27520932
[TBL] [Abstract][Full Text] [Related]
5. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
[TBL] [Abstract][Full Text] [Related]
6. Radioembolization with
Braat AJAT; Ahmadzadehfar H; Kappadath SC; Stothers CL; Frilling A; Deroose CM; Flamen P; Brown DB; Sze DY; Mahvash A; Lam MGEH
Cardiovasc Intervent Radiol; 2020 Feb; 43(2):246-253. PubMed ID: 31646375
[TBL] [Abstract][Full Text] [Related]
7. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes.
Memon K; Lewandowski RJ; Mulcahy MF; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Gates VL; Atassi B; Newman S; Omary RA; Benson AB; Salem R
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):887-94. PubMed ID: 22137020
[TBL] [Abstract][Full Text] [Related]
8. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases.
King J; Quinn R; Glenn DM; Janssen J; Tong D; Liaw W; Morris DL
Cancer; 2008 Sep; 113(5):921-9. PubMed ID: 18618495
[TBL] [Abstract][Full Text] [Related]
9.
Schaarschmidt BM; Wildgruber M; Kloeckner R; Nie J; Steinle V; Braat AJAT; Lohoefer F; Kim HS; Lahner H; Weber M; Theysohn J
J Nucl Med; 2022 May; 63(5):679-685. PubMed ID: 34475236
[TBL] [Abstract][Full Text] [Related]
10. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
[No Abstract] [Full Text] [Related]
11. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.
Rhee TK; Lewandowski RJ; Liu DM; Mulcahy MF; Takahashi G; Hansen PD; Benson AB; Kennedy AS; Omary RA; Salem R
Ann Surg; 2008 Jun; 247(6):1029-35. PubMed ID: 18520231
[TBL] [Abstract][Full Text] [Related]
12. Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors.
Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
J Gastroenterol Hepatol; 2017 Sep; 32(9):1617-1623. PubMed ID: 28132407
[TBL] [Abstract][Full Text] [Related]
13. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: initial experience at a single center.
Arslan N; Emi M; Alagöz E; Ustünsöz B; Oysul K; Arpaci F; Uğurel S; Beyzadeoğlu M; Ozgüven MA
Vojnosanit Pregl; 2011 Apr; 68(4):341-8. PubMed ID: 21627019
[TBL] [Abstract][Full Text] [Related]
14. Radioembolization with
Braat AJAT; Kappadath SC; Ahmadzadehfar H; Stothers CL; Frilling A; Deroose CM; Flamen P; Brown DB; Sze DY; Mahvash A; Lam MGEH
Cardiovasc Intervent Radiol; 2019 Mar; 42(3):413-425. PubMed ID: 30603975
[TBL] [Abstract][Full Text] [Related]
15. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
Baum RP; Wang P; Jakobsson V; Zhao T; Schuchardt C; Khong PL; Zhang J
Theranostics; 2024; 14(1):133-142. PubMed ID: 38164147
[No Abstract] [Full Text] [Related]
16. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.
Martin LK; Cucci A; Wei L; Rose J; Blazer M; Schmidt C; Khabiri H; Bloomston M; Bekaii-Saab T
Clin Colorectal Cancer; 2012 Sep; 11(3):195-9. PubMed ID: 22277350
[TBL] [Abstract][Full Text] [Related]
17. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
[TBL] [Abstract][Full Text] [Related]
19. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
[TBL] [Abstract][Full Text] [Related]
20. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres.
Paprottka PM; Hoffmann RT; Haug A; Sommer WH; Raessler F; Trumm CG; Schmidt GP; Ashoori N; Reiser MF; Jakobs TF
Cardiovasc Intervent Radiol; 2012 Apr; 35(2):334-42. PubMed ID: 21847708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]